Journal of Neuro-Oncology

, Volume 103, Issue 3, pp 797–801 | Cite as

mTORC1 activation in childhood ependymoma and response to sirolimus

  • Daniel C. Bowers
  • Blanka Kucejova
  • Linda Margraf
  • Lynn Gargan
  • James Brugarolas
Case Report

Abstract

Recurrent ependymomas are considered rarely responsive to chemotherapy and often have a dismal prognosis after tumor progression. Below is a brief report of a 6 year old child with a multiply progressive ependymoma whose tumor had a near complete response to sirolimus that was durable for 18 months. Immunohistochemistry for phosphorylated S6, which has been reported to be associated with tumor sensitivity to mTORC1 inhibitors, was positive in this patient’s tumor.

Keywords

Ependymoma Sirolimus Rapamycin mTORC1 

References

  1. 1.
    Merchant TE, Mulhern RK, Krasin MJ et al (2004) Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 22:3156–3162PubMedCrossRefGoogle Scholar
  2. 2.
    Bouffet E, Capra M, Bartels U (2009) Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Childs Nerv Syst 25:1293–1301PubMedCrossRefGoogle Scholar
  3. 3.
    Goldwein JW, Glauser TA, Packer RJ et al (1990) Recurrent intracranial ependymomas in children. Survival, patterns of failure, and prognostic factors. Cancer 66:557–563PubMedCrossRefGoogle Scholar
  4. 4.
    Sangra M, Thorp N, May P et al (2009) Management strategies for recurrent ependymoma in the pediatric population. Childs Nerv Syst 25:1283–1291PubMedCrossRefGoogle Scholar
  5. 5.
    Merchant TE, Boop FA, Kun LE et al (2008) A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys 71:87–97PubMedCrossRefGoogle Scholar
  6. 6.
    Kieran MW, Turner CD, Rubin JB et al (2005) A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27:573–581PubMedCrossRefGoogle Scholar
  7. 7.
    Brugarolas J, Lotan Y, Watumull L et al (2008) Sirolimus in metatastic renal cell carcinoma. J Clin Oncol 26:3457–3460PubMedCrossRefGoogle Scholar
  8. 8.
    Stallone G, Schena A, Infante B et al (2005) Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 352:1317–1323PubMedCrossRefGoogle Scholar
  9. 9.
    Wagner AJ, Malinowska-Kolodziej I, Morgan JA et al (2010) Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 28:835–840PubMedCrossRefGoogle Scholar
  10. 10.
    Wolff N, Kabbani W, Bradley T et al (2010) Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol 28:e65–e68PubMedCrossRefGoogle Scholar
  11. 11.
    Bissler JJ, McCormack FX, Young LR et al (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140–151PubMedCrossRefGoogle Scholar
  12. 12.
    Franz DN, Leonard J, Tudor C et al (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490–498PubMedCrossRefGoogle Scholar
  13. 13.
    Motzer RJ, Molina AM (2009) Targeting renal cell carcinoma. J Clin Oncol 27:3274–3276PubMedCrossRefGoogle Scholar
  14. 14.
    Witzig TE, Geyer SM, Ghobrial I et al (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347–5356PubMedCrossRefGoogle Scholar
  15. 15.
    Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294–5304PubMedCrossRefGoogle Scholar
  16. 16.
    Fouladi M, Laningham F, Wu J et al (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 25:4806–4812PubMedCrossRefGoogle Scholar
  17. 17.
    Houghton PJ, Morton CL, Kolb EA et al (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50:799–805PubMedCrossRefGoogle Scholar
  18. 18.
    Iwenofu OH, Lackman RD, Staddon AP et al (2007) Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 21:231–237PubMedCrossRefGoogle Scholar
  19. 19.
    Cho D, Signoretti S, Dabora S et al (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5:379–385PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Daniel C. Bowers
    • 1
    • 4
    • 6
    • 7
  • Blanka Kucejova
    • 2
    • 3
    • 4
  • Linda Margraf
    • 5
  • Lynn Gargan
    • 6
  • James Brugarolas
    • 3
    • 4
    • 5
  1. 1.Department of PediatricsUniversity of Texas Southwestern Medical School at DallasDallasUSA
  2. 2.Department of Internal MedicineUniversity of Texas Southwestern Medical School at DallasDallasUSA
  3. 3.Department of Developmental BiologyUniversity of Texas Southwestern Medical School at DallasDallasUSA
  4. 4.Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical School at DallasDallasUSA
  5. 5.Department of PathologyUniversity of Texas Southwestern Medical School at DallasDallasUSA
  6. 6.Department of Neuro-OncologyCenter for Cancer and Blood Disorders, Children’s Medical Center – DallasDallasUSA
  7. 7.Division of Pediatric Hematology-OncologyUniversity of Texas Southwestern Medical School at DallasDallasUSA

Personalised recommendations